LEO Pharma and Boehringer Ingelheim have entered into a partnership to commercialise and advance the development of ...

Boehringer Ingelheim and SoundTalks end their partnership, but what does this mean for pig farmers? Find out about the future ...

the white paper underscores a widespread crisis of underappreciation, operational strain and burnout, directly impacting the ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Philadelphia, PA, July 21, 2025 - NodThera, a leading clinical-stage biotech delivering a paradigm shift in the treatment of ...

For the second time this year, Leo Pharma has struck a partnership with a major drugmaker, this time paying Boehringer ...

This month in the Zantac litigation, the Delaware Supreme Court tossed all the plaintiffs’ experts in thousands of cases, ...

Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab) ...

LEO Pharma A/S agreed to acquire the global rights for skin disease drug Spevigo from Boehringer Ingelheim GmbH, as the ...

Boehringer Ingelheim, one of the industry leading investors in research and development in innovative life expectancy ...

Boehringer Ingelheim recently announced the start of the THULITE phase II clinical study ( NCT06962839 ). THULITE will ...

Boehringer Ingelheim set to receive EUR 90 million as upfront payment, along with milestone payments and tiered royalties.